SAB Biotherapeutics, Inc. (SABS) Stock Score, Valuation & Financial Research

SAB Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SABS

SAB Biotherapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.09. These figures are a research snapshot, not a buy or sell recommendation.

What SAB Biotherapeutics, Inc. does

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

SAB Biotherapeutics is a clinical-stage biopharmaceutical company that generates revenue primarily through research and development collaborations and government contracts. The company utilizes its proprietary DiversitAb platform and Transchromosomic (Tc) Bovine technology to develop fully human, multi-targeted, high-potency polyclonal antibodies for immune and autoimmune disorders, currently focusing on clinical-stage therapeutic candidates.

Products and services

  • The company's primary product candidate is SAB-142, a human anti-thymocyte immunoglobulin (hATG) currently in Phase 2b clinical development for the treatment of Type 1 Diabetes.

Brands and product families

  • SAB-142 — Lead therapeutic candidate for Type 1 Diabetes. Source
  • DiversitAb — Proprietary drug development production system. Source

Customer types

Government agencies; Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party CROs to conduct clinical trials and manage data collection. Source

Business relationships and partnerships

  • Sanofi — Strategic investor and partner that participated in a $175 million private placement to fund the Phase 2b SAFEGUARD study. Source

Competitors and product-market comparisons

  • Companies developing anti-thymocyte globulin (ATG) therapies — Competitors include companies developing alternative therapies for Type 1 Diabetes and other autoimmune conditions. Source

Business strengths to evaluate

  • Proprietary DiversitAb and Tc-Bovine platform technology Source
  • Strong cash position following $175 million financing Source

Business risks and research considerations

  • History of operating losses and potential need for additional capital Source
  • Dependence on the success of the lead candidate SAB-142 Source
  • Risks associated with clinical trial enrollment and regulatory approval Source

Sources: Company research source · Sanofi

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SABS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.09
Market capitalization:
280.69M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.78M
Free cash flow:
USD -45.71M
Cash:
USD 8.27M
Total debt:
USD 5.13M
EPS:
USD 3.57
P/E ratio:
0.9x

What stands out

  • Free cash flow is USD -45.71M, negative for the stored period.
  • The balance sheet shows USD 8.27M of cash versus USD 5.13M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.14M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SABS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SABS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SABS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SABS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SABS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SABS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.